Reports: Roche raises DNA offer to $95 a share

Genentech's board may be ready to seal the deal after all. Although the company urged shareholders to sit tight after Roche uppeds its bid to $93 a share on Friday, the Wall Street Journal is reporting that the biotech and Roche were in discussions through the weekend. Sources close to the matter tell the WSJ that Roche has again raised its tender offer to $95 a share. A deal could be announced as soon as the close of the trading day.

The new offer values Genentech at $46.7 billion. DNA is currently up 2.4 percent, trading around $92.93.

- check out the WSJ report

Suggested Articles

CEPI, which started to help prepare the world for new outbreaks, has awarded Inovio and Moderna money for vaccine work against the new coronavirus.

The real estate impresario that built a chain of upscale drug recovery facilities is now building a gene and cell therapy CDMO near Philadelphia.

The seven-year Astellas venture served as a model for Amgen's recent $2.7 billion tie-up with BeiGene in China—and now it's amping up there, too.